Spots Global Cancer Trial Database for hpv infections

Every month we try and update this database with for hpv infections cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females	NCT05372016	HPV Infections Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS	Experimental: E... Active Comparat...	16 Years - 26 Years	Shanghai Bovax Biotechnology Co., Ltd.
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)	NCT00943722	Cervical Cancer... Vulvar Cancer Vaginal Cancer Genital Lesions PAP Test Abnorm... HPV Infections	V503	9 Years - 26 Years	Merck Sharp & Dohme LLC
An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)	NCT00635830	HPV Infections	Quadrivalent Hu...	9 Years - 26 Years	Merck Sharp & Dohme LLC
Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China	NCT01021904	HPV Infections Precancerous Di... Cervical Cancer HPV Related Dis...	Gardasil (VLP, ...	13 Years - 15 Years	ChineseAMS
Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China	NCT01021904	HPV Infections Precancerous Di... Cervical Cancer HPV Related Dis...	Gardasil (VLP, ...	13 Years - 15 Years	ChineseAMS
Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China	NCT01021904	HPV Infections Precancerous Di... Cervical Cancer HPV Related Dis...	Gardasil (VLP, ...	13 Years - 15 Years	ChineseAMS
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)	NCT00943722	Cervical Cancer... Vulvar Cancer Vaginal Cancer Genital Lesions PAP Test Abnorm... HPV Infections	V503	9 Years - 26 Years	Merck Sharp & Dohme LLC
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)	NCT00411749	HPV Infections	Quadrivalent Hu... Comparator: Pla...	9 Years - 17 Years	Merck Sharp & Dohme LLC
Significance of the High-risk Hpv Viral Load	NCT00682812	HPV Infections	2 cervical taki... 2 cervical taki... 2 cervical taki...	18 Years -	Assistance Publique Hopitaux De Marseille
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls	NCT00956553	HPV Infections	Cervarix Gardasil	13 Years - 15 Years	Public Health England
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)	NCT00411749	HPV Infections	Quadrivalent Hu... Comparator: Pla...	9 Years - 17 Years	Merck Sharp & Dohme LLC
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine	NCT05371353	HPV Infections Cervical Cancer... Vaginal Cancer Genital Wart CIN1 CIN2 CIN3		9 Years - 45 Years	Shanghai Bovax Biotechnology Co., Ltd.
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)	NCT00733122	HPV Infections	Quadrivalent Hu...	16 Years - 26 Years	Merck Sharp & Dohme LLC
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years	NCT04895020	HPV Infections Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN 3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS	9-valent HPV va...	9 Years - 45 Years	Shanghai Bovax Biotechnology Co., Ltd.
Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population	NCT00847340	Genital Warts HPV Infections	Biopsy Excision...	18 Years - 45 Years	La Fundacion para la Investigacion y el Desarrollo
Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191	NCT01086709	Cervical Neopla... HPV Infections		21 Years - 30 Years	National Institutes of Health Clinical Center (CC)
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine	NCT03900572	HPV Infections	HPV Vaccine Placebo	9 Years - 45 Years	Shanghai Zerun Biotechnology Co.,Ltd
Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population	NCT00847340	Genital Warts HPV Infections	Biopsy Excision...	18 Years - 45 Years	La Fundacion para la Investigacion y el Desarrollo
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)	NCT00733122	HPV Infections	Quadrivalent Hu...	16 Years - 26 Years	Merck Sharp & Dohme LLC
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years	NCT05027776	HPV Infections Cervical Cancer... Vaginal Cancer Genital Wart CIN1 CIN2 CIN3	2-doses Group a... 3-doses Group a... 3-doses Group a...	9 Years - 26 Years	Shanghai Bovax Biotechnology Co., Ltd.
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)	NCT00496626	Papillomavirus ...	Quadrivalent Hu... Comparator: Pla...	9 Years - 45 Years	Merck Sharp & Dohme LLC
A Study to Identify Markers in Blood and Tissue of HPV Clearance	NCT00711815	HPV Infections		19 Years -	University of Alabama at Birmingham
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)	NCT00496626	Papillomavirus ...	Quadrivalent Hu... Comparator: Pla...	9 Years - 45 Years	Merck Sharp & Dohme LLC
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females	NCT05372016	HPV Infections Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS	Experimental: E... Active Comparat...	16 Years - 26 Years	Shanghai Bovax Biotechnology Co., Ltd.

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: